Higher baseline inflammatory markers like IL6 and TNF track with more heart disease, diabetes, cognitive decline, and earlier mortality in older adults. With tirzepatide on board, that background fire drops: It lowers proinflammatory cytokines: Animal and cell studies show tirzepatide cuts classic inflammatory messengers, including IL6, IL1, and TNF, while boosting antiinflammatory cytokines like IL4 and IL10. It calms hot metabolic tissues: In obese mice, tirzepatide reduces inflammatory macrophages in visceral fat and improves insulin signaling as that tissue quiets down. GLP1based drugs with similar signaling reduce vascular and kidney inflammation, which lines up with the lower cardiovascular and kidney event rates seen in large outcome trials. Turn that into real life and you get less background ache, less immune noise beating up vessels and organs, and a lower inflammatory drag on the heart, brain, and kidneys as the decades add up
GLP-1 programs use a separate checkout path
doi: 10.1210/jcem.76.4.8473405 43 GallwitzBWittMFlschURCreutzfeldtWSchmidtWE
Because fumarate is a direct, naturally occurring intermediate in the Krebs cycle, this specific form provides a powerful dual-action benefit
(Serena did not disclose which specific medication she is on
Roddy D, McCarthy P, Nerney D, et al